1240390-32-2

Basic information

• Product Name: 3-AMino-4-hydroxy-tetrahy...
• Synonyms: 3-AMino-4-hydroxy-tetrahy...;3-AMino-4-hydroxy-tetrahydropyran;(3S,4S)-3-AMino-4-hydroxy...;(3S,4S)-3-AMino-4-hydroxy-tetrahydropyran;(3S,4S)-3-AMinotetrahydro-2H-Pyran-4-ol;(3S,4S)-3-aminooxan-4-ol
• CAS NO: 1240390-32-2
• Molecular Formula: C₅H₁₁NO₂
• Molecular Weight: 117.15
• Mol File: 1240390-32-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 246.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.147±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.25±0.40(Predicted)
• CAS DataBase Reference: 3-AMino-4-hydroxy-tetrahy...(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMino-4-hydroxy-tetrahy...(1240390-32-2)
• EPA Substance Registry System: 3-AMino-4-hydroxy-tetrahy...(1240390-32-2)

Safety Data

• Hazardous Substances Data: 1240390-32-2(Hazardous Substances Data)

Usage

Description

3-Amino-4-hydroxy-tetrahydro..., also known as 2-Amino-1,5-anhydro-2,4-dideoxy-L-threo-Pentitol, is a chemical compound that plays a significant role in the development of pharmaceutical agents. It possesses unique structural features that enable it to interact with specific biological targets, making it a valuable component in the creation of therapeutic molecules.

Uses

Used in Pharmaceutical Industry:
3-Amino-4-hydroxy-tetrahydro... is used as a key component in the preparation of ERR-α inverse agonists for the treatment of cancer. These inverse agonists target the estrogen-related receptor alpha (ERR-α), a protein that plays a role in cellular metabolism and energy homeostasis. By modulating the activity of ERR-α, these inverse agonists can potentially inhibit cancer cell growth and proliferation, offering a novel therapeutic approach for cancer treatment.

Upstream product

• 286-22-6 3,4-epoxytetrahydropyran 
• 3174-74-1 dihydropyran 
• 25637-16-5 4-bromotetrahydro-2H-pyran 
• 1268516-33-1 benzyl ((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)carbamate 
• 1268516-32-0 benzyl ((3S)-4-oxotetrahydro-2H-pyran-3-yl)carbamate 
• 1268516-31-9 (3S)-4,4-dimethoxytetrahydro-2H-pyran-3-amine 
• 693245-80-6 4,4-dimethoxy-5,6-dihydro-2H-pyran-3(4H)-one 
• 104681-92-7 4,4-dimethoxytetrahydro-2H-pyran-3-ol 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 1240390-31-1 1,5-anhydro-2,4-dideoxy-2-{[(1R)-1-phenylethyl]amino}-L-threo-pentitol 
• 1240390-30-0 (3S,4S)-3-((S)-1-phenylethylamino)tetrahydro-2H-pyran-4-ol 

Downstream Products

• 1240390-33-3 1,5-anhydro-2-((tert-butoxycarbonyl)amino)-2,4-dideoxy-L-threo-pentitol 
• 1240390-36-6 tert-butyl ((3R,4R)-4-aminotetrahydro-2H-pyran-3-yl)carbamate 
• 1439909-39-3 tert-butyl ((3R,4R)-4-((5-carbamoyl-4-((3-chlorophenyl)amino)pyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-yl)carbamate 
• 1439906-07-6 2-(((3R,4R)-3-aminotetrahydro-2H-pyran-4-yl)amino)-4-((3-chlorophenyl)amino)pyrimidin-5-carboxamide 

Relevant articles and documents

SELECTIVE KINASE INHIBITORS

Provided are pyrimidine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

PYRIDOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as ALzheimer?s disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor